Company intelligence / Profile preview
Linnane Pharma
Sweden
- Ownership
- Private
- Development stage
- Other
01
Overview
Linnane Pharma, through its subsidiaries, has achieved clinical proof of concept for novel cancer therapeutics (Hamlet Pharma, Phase 1/2 bladder cancer trial) and for immunotherapy alternatives to antibiotics (SelectImmune Pharma, clinical validation in severe bladder pain syndrome). Additional projects are in earlier stages, backed by a strong patent portfolio[1][2].
- Therapeutic areas
- OncologyInfectious DiseasesImmunology
- Modalities
- Small moleculeSynthetic peptideImmunotherapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Hamlet BioPharma
Beyond the preview
Go deeper on Linnane Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Linnane Pharma.